B cells baffle T cells

By Kate McDonald
Monday, 19 January, 2009

Sydney researchers investigating the role of the cytokine known as BAFF have found that while it has a normal pro-inflammatory function, it also has a surprising role in regulating T cell response, in an anti-inflammatory manner.

BAFF (B cell activation of the TNF family) is considered to be primarily involved in B cell activation, as its name suggests, but previous studies have shown that it may also be involved in the regulation of T cell response.

In vitro studies have shown that higher levels of BAFF co-stimulates both human and mouse T cells, and in vivo studies have shown that BAFF-transgenic mice display exaggerated T-dependent antigen responses.

It has also been observed that loss of BAFF signalling impairs the development of antigen-specific T cell responses.

All of this data shows that BAFF has a pro-inflammatory role with regard to T cells.

Now, however, researchers led by PhD student Stacey Walters and Dr Shane Grey of the Garvan Institute in Sydney have found that when BAFF is over-expressed, it has also has an anti-inflammatory role, with effector T cells unable to do their duty.

In fact, in BAFF transgenic mice, T cell effector responses were profoundly compromised, to the extent of accepting tissue allografts.

The reason behind this is that increased levels of BAFF expands the number of CD4+ Foxp3+ regulatory T cells, which are known to inhibit immune responses. It was not thought previously that B cells had a role in T regulatory cells, but this study, the researchers say, shows that BAFF has a complex, dichotomous role to play in immunity.

The work is published in the Journal of Immunology.

Related News

Exclusive colostrum intake may reduce risk of food allergies

Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...

Sunscreen and supplements can lower your vitamin D levels

People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...

Low-dose drug prevents diabetes progression in young people

A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd